Dental maturity is associated with skeletal maturity, which is advanced in girls with central precocious puberty (CPP). We investigated the performance of dental maturity as a screening method for CPP using mandibular second premolar and molar calcification stages, assessed the associated anthropometric and laboratory factors, and evaluated pubertal response predictors using the gonadotropin-releasing hormone stimulation test (GnRHST) in prepubertal and pubertal girls. A prospective case-control study was conducted in girls, aged 7.0–8.9 years, classified into pubertal (peak luteinizing hormone [LH] after GnRHST ≥ 5 IU/L), prepubertal (peak LH < 5 IU/L), and control groups. Auxological and biochemical tests, panoramic radiographs, and GnRHSTs in participants with breast development were conducted. Dental maturity was assessed using the Demirjian index (DI). We included 103 girls (pubertal, 40; prepubertal, 19; control, 44). Chronological age (CA) was not significantly different between groups. Bone age (BA) and BA advancement was higher in the pubertal and prepubertal groups. Increased DI values at the mandibular second premolar and molar were significantly associated with CA, BA, BA advancement, height standard deviation score (SDS), peak LH after GnRHST, and insulin-like growth factor-I (IGF-I) (all P < 0.05). Moreover, odds ratio (OR) of the mandibular second premolar and molar (a DI value of ≥ E) for predicting a positive response to GnRHST was 8.7 (95% confidence intervals [CI], 2.9–26.1) and 5.2 (95% CI, 2.2–12.7), respectively. Dental maturity was a strong predictor for diagnosing CPP. Determining dental maturity in girls with suspected precocious puberty might help determine the performance of GnRHSTs.
Bicuspid ; Breast ; Case-Control Studies ; Diagnosis ; Female* ; Gonadotropin-Releasing Hormone* ; Humans ; Luteinizing Hormone ; Mass Screening ; Methods ; Molar ; Odds Ratio ; Prospective Studies ; Puberty, Precocious*

BACKGROUND: Transfusion guidelines play an important role for the appropriate use and quality assurance of blood and transfusion services. The Korean national transfusion guideline was developed in 2009 and went under full amendment in 2016. The purpose of this study was to investigate the awareness and practicality of the transfusion guideline in Korea. METHODS: Questionnaires about the Korean national transfusion guideline were sent by traditional mail or e-mail to a total of 1,179 clinicians, 32 academic societies, and 6 institutions. RESULTS: Three hundred and seventy-four answers were received; a response rate of 30.7%. The proportion of respondents with good awareness of the guideline was 23.3%, which is a significant increase compared with 10.9% in 2008. Respondents with good awareness were more dependent on the transfusion guideline when making transfusion decisions. CONCLUSION: There was a considerable increase in the awareness of the national transfusion guideline in Korea.
Electronic Mail ; Korea* ; Postal Service ; Surveys and Questionnaires

BACKGROUND: The morbidity and mortality of Legionnaires' disease are not established in Korea, because patients with community-acquired pneumonia (CAP) have rarely been investigated for Legionella. An assay for Legionella antigen in urine has been approved as one of the diagnostic criteria of Legionnaires' disease. Binax Now(TM) Legionella Urinary Antigen Test (LUA) was introduced in Asan Medical Center in July 2002. The purpose of this study was to evaluate the clinical relevance of positive LUA. METHODS: During the 39-month period from July 2002 to September 2005, the medical records of LUA-positive patients were reviewed for demographic findings, laboratory findings, clinical diagnosis, antimicrobial treatment, outcome, and acquisition of infections. Diagnosis of Legionnaires' disease was based on National Nosocomial Infections Surveillance (NNIS) criteria for defining nosocomial pneumonia. RESULTS: Seven (0.3%) of the 2443 patients tested for LUA were positive. All 7 patients were consistent with the diagnostic criteria of Legionnaires' disease; six patients were diagnosed with CAP and one patient was admitted due to nosocomial pneumonia. Six patients were treated with azithromycin or ciprofloxacin but one patient was not treated for Legionella infection. With the report of LUApositive results, a Legionella-targeted treatment was started in two patients and an inappropriate empirical therapy was ceased in one patient. All patients treated with Legionella-targeted treatment improved clinically except one who died of adult respiratory distress syndrome at the first hospital day. CONCLUSIONS: Positive LUA is useful in diagnosing Legionnaire's disease at an early stage and in helping to initiate appropriate treatments in a tertiary-care hospital in Korea.
Azithromycin ; Chungcheongnam-do ; Ciprofloxacin ; Cross Infection ; Diagnosis ; Humans ; Korea* ; Legionella* ; Legionnaires' Disease ; Medical Records ; Mortality ; Pneumonia ; Respiratory Distress Syndrome, Adult

Background: Turnaround time (TAT) is a major quality control indicator and can be defined differently depending on the starting point in the examination process. To determine effective TAT management plan, we investigated the status of TAT management in clinical laboratories in Korea. Methods: A questionnaire was developed using Google web pages and a questionnaire survey was conducted at 30 clinical laboratories in laboratory medicine from September 1 to 11 in 2018. Questions were developed regarding management time, starting point standards, management goals, most problematic stages of delayed TAT, clinical measures, and shortening barriers for investigation. Results: All clinical laboratories requested to undertake the survey completed the questionnaire (response rate 100%, 30/30) and answered that they were setting and managing TAT for all tests. Many laboratories (33%) set the TAT starting point as the reception stage, prior to commencing centrifugation. Of the surveyed laboratories, 37% achieved a TAT of 120 min or more for general tests, 27% met the TAT of 90 min for pre-clinic tests, and 77% met the TAT of 60 min for completion of stat tests. Most laboratories (67%) reported that the most delayed stage was pre-analysis, and 50% reported that the greatest obstacle to shortening TAT was the ratio of stat and pre-clinic tests to general tests. Conclusions The laboratories participating in this survey set a TAT based on various criteria and were performing management for TAT improvement. The results of this study can be used as basic data to guide efficient TAT management.

Background: Turnaround time (TAT) is a major quality control indicator and can be defined differently depending on the starting point in the examination process. To determine effective TAT management plan, we investigated the status of TAT management in clinical laboratories in Korea. Methods: A questionnaire was developed using Google web pages and a questionnaire survey was conducted at 30 clinical laboratories in laboratory medicine from September 1 to 11 in 2018. Questions were developed regarding management time, starting point standards, management goals, most problematic stages of delayed TAT, clinical measures, and shortening barriers for investigation. Results: All clinical laboratories requested to undertake the survey completed the questionnaire (response rate 100%, 30/30) and answered that they were setting and managing TAT for all tests. Many laboratories (33%) set the TAT starting point as the reception stage, prior to commencing centrifugation. Of the surveyed laboratories, 37% achieved a TAT of 120 min or more for general tests, 27% met the TAT of 90 min for pre-clinic tests, and 77% met the TAT of 60 min for completion of stat tests. Most laboratories (67%) reported that the most delayed stage was pre-analysis, and 50% reported that the greatest obstacle to shortening TAT was the ratio of stat and pre-clinic tests to general tests. Conclusions The laboratories participating in this survey set a TAT based on various criteria and were performing management for TAT improvement. The results of this study can be used as basic data to guide efficient TAT management.

Herein, we report a case in which cholestasis caused discrepancy in high-density lipoprotein (HDL)-cholesterol levels measured using various methods. The discrepancy in HDL-cholesterol level originated from the abnormal increase in the level of an unusual lipoprotein, apo E-rich HDL, in the patient's serum. An abnormal slow alpha-migrating lipoprotein was observed on agarose gel electrophoresis, and an abnormal large-sized HDL was observed in a lipoprotein subfraction study. The level of apolipoprotein E was elevated.
Apolipoproteins ; Cholestasis ; Electrophoresis, Agar Gel ; Lipoproteins

Herein, we report a case in which cholestasis caused discrepancy in high-density lipoprotein (HDL)-cholesterol levels measured using various methods. The discrepancy in HDL-cholesterol level originated from the abnormal increase in the level of an unusual lipoprotein, apo E-rich HDL, in the patient's serum. An abnormal slow alpha-migrating lipoprotein was observed on agarose gel electrophoresis, and an abnormal large-sized HDL was observed in a lipoprotein subfraction study. The level of apolipoprotein E was elevated.
Apolipoproteins ; Cholestasis ; Electrophoresis, Agar Gel ; Lipoproteins

BACKGROUND: Maternal serum triple marker screening has been covered by the medical insurance system in Korea since December 2004. The number of tests is on the increase, but an external quality control program and a basic survey have not been established yet. The aim of this study was to port the survey of prenatal screening tests. METHODS: Three different quality control specimens were prepared using the sera obtained from 100 women who were in the 15th to 20th week of pregnancy and visited Asan Medical Center during May 2005. We assumed that the three specimens belonged to the first day of 15 weeks, third day of 16 weeks, and second day of 19 weeks, respectively, and sent them to 10 laboratories. Nine laboratories replied to the survey. We analyzed concentrations, multiples of medians (MoMs), and risk estimates. RESULTS: The coefficients of variance of MoM were 32.1-32.6% for alpha-fetoprotein, 15.3-19.8% for unconjugated estriol, 6.3-12.5% for human chorionic gonadotropin, and 12.9-18.2% for inhibin-A. In Down syndrome risk estimation for specimen-2, six of the eight laboratories that used the triple test reported the screen positive, but two laboratories reported negative. Three of five laboratories using the quadruple test reported the screen positive, and two laboratories reported negative. In case of neural tube defect, all laboratories except one reported all specimens the screen negative. In case of Edward syndrome, all laboratories reported all specimens the screen negative. CONCLUSIONS: Since MoMs and risk estimates showed a wide variation among the participating laboratories in this survey, an external quality control and the standardization of the variables seemed warranted.
Biological Markers/*blood ; Female ; Humans ; Korea ; Pregnancy ; Prenatal Diagnosis/*standards